Cantor Fitzgerald Has Negative View of CVRx FY2025 Earnings

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for CVRx in a research report issued on Wednesday, February 5th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($1.90) per share for the year, down from their previous estimate of ($1.58). Cantor Fitzgerald currently has a "Overweight" rating and a $14.00 target price on the stock. The consensus estimate for CVRx's current full-year earnings is ($1.89) per share.

A number of other brokerages have also issued reports on CVRX. Craig Hallum raised their price target on CVRx from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. Lake Street Capital boosted their price target on CVRx from $12.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Piper Sandler lifted their target price on CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. William Blair raised CVRx from a "market perform" rating to an "outperform" rating in a research report on Tuesday, January 14th. Finally, Canaccord Genuity Group upped their price objective on shares of CVRx from $22.00 to $23.00 and gave the stock a "buy" rating in a research note on Wednesday, February 5th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.83.

CVRx Trading Down 0.7 %

CVRX stock traded down $0.11 during mid-day trading on Friday, reaching $14.79. 55,688 shares of the stock traded hands, compared to its average volume of 262,748. The company has a debt-to-equity ratio of 0.76, a quick ratio of 10.23 and a current ratio of 11.32. CVRx has a one year low of $6.40 and a one year high of $24.55. The stock has a market capitalization of $358.68 million, a PE ratio of -5.49 and a beta of 1.30. The business has a 50-day moving average price of $14.67 and a two-hundred day moving average price of $11.85.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 96.36%.

Institutional Investors Weigh In On CVRx

A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in CVRx during the 3rd quarter worth approximately $108,000. Calamos Advisors LLC acquired a new stake in CVRx during the 4th quarter worth about $134,000. XTX Topco Ltd purchased a new position in shares of CVRx during the 3rd quarter valued at about $150,000. Jane Street Group LLC lifted its holdings in shares of CVRx by 36.1% in the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company's stock valued at $168,000 after buying an additional 5,053 shares during the period. Finally, Barclays PLC grew its holdings in CVRx by 312.5% during the third quarter. Barclays PLC now owns 19,067 shares of the company's stock worth $169,000 after acquiring an additional 14,445 shares during the period. Institutional investors and hedge funds own 75.27% of the company's stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.